Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with beta-thalassaemia intermedia.

β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14

Atrial Fibrillation and Beta Thalassemia Major: The Predictive Role of the 12-lead Electrocardiogram Analysis. Indian Pacing Electrophysiol J (2014) 0.84

The role of the atrial electromechanical delay in predicting atrial fibrillation in beta-thalassemia major patients. J Interv Card Electrophysiol (2016) 0.78

Covert brain ischaemia in splenectomised adults with thalassemia intermedia: An emerging entity. Thromb Haemost (2010) 0.75

Intracranial Blood Flow Velocity in Patients with β-Thalassemia Intermedia Using Transcranial Doppler Sonography: A Case-Control Study. Anemia (2011) 0.75

Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood (2007) 2.52

Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27

Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol (2008) 2.25

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest (2010) 2.18

The hypercoagulable state in thalassemia. Blood (2002) 1.88

Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood (2008) 1.72

Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol (2007) 1.63

Cerebrovascular accident in beta-thalassemia major (beta-TM) and beta-thalassemia intermedia (beta-TI). Am J Hematol (2008) 1.59

Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol (2007) 1.45

Amelioration of oxidative stress in red blood cells from patients with beta-thalassemia major and intermedia and E-beta-thalassemia following administration of a fermented papaya preparation. Phytother Res (2010) 1.42

Non-transfusion-dependent thalassemias. Haematologica (2013) 1.21

Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica (2010) 1.19

β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14

Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol (2010) 1.10

Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol (2012) 1.04

Factor XIII Deficiency. Semin Thromb Hemost (2009) 0.97

[The prevention programs for beta thalassemia in the Jezreel and Eiron valleys: results of fifteen years experience]. Harefuah (2002) 0.91

Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann N Y Acad Sci (2009) 0.90

The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia. Ann N Y Acad Sci (2010) 0.89

Exploring the role of hepcidin, an antimicrobial and iron regulatory peptide, in increased iron absorption in beta-thalassemia. Ann N Y Acad Sci (2005) 0.88

Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. Br J Haematol (2011) 0.87

Breast myeloma: a report of 3 cases with fine needle aspiration cytologic findings. Acta Cytol (2005) 0.86

Severe infections in thalassaemic patients: prevalence and predisposing factors. Br J Haematol (2006) 0.84

Fermented papaya preparation as redox regulator in blood cells of beta-thalassemic mice and patients. Phytother Res (2008) 0.82

Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML). Am J Hematol (2004) 0.81

Hepcidin and Hfe in iron overload in beta-thalassemia. Ann N Y Acad Sci (2010) 0.81

Cerebral infarction in β-thalassemia intermedia: breaking the silence. Thromb Res (2012) 0.78

Frequency and distribution of asymptomatic brain lesions in patients with β-thalassemia intermedia. Ann Hematol (2012) 0.78

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. Eur J Haematol (2009) 0.78

Decreased hemolysis following administration of antioxidant-fermented papaya preparation (FPP) to a patient with PNH. Ann Hematol (2009) 0.76

Sustained complete remission following a combination of very low intensity chemotherapy with rituximab in an elderly patient with Burkitt's lymphoma. Haematologica (2002) 0.75